Intravenous administration of puppy deciduous teeth stem cells in degenerative valve disease

Petchdee, Soontaree; Sompeewong, Sarunya

doi:10.14202/vetworld.2016.1429-1434

Cited by 11 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stem cells are also capable of migrating to sites of inflammation following intravenous administration, as previous studies have demonstrated. [31][32][33] Chemokines such as SDF-1 34 and MCP-1 35 released by inflammatory stimuli provide a potent stimulus for mesenchymal stem cell recruitment, and these cytokines are known to be produced in the joints of animals with osteoarthritis. 36,37 Pulmonary trapping may interfere with this function, 38,39 which may explain why mesenchymal stem cells were detected in the joint fluid of only four dogs in our study.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study

Olsen

Johnson

Webb

et al. 2019

Vet Comp Orthop Traumatol

View full text Add to dashboard Cite

Objectives The aim of this study was to evaluate the safety and collect pilot data measuring clinical effects of intravenously administered, adipose-derived, culture-expanded, allogeneic mesenchymal stem cells in dogs with elbow osteoarthritis. Materials and Methods Dogs (n = 13) with naturally occurring elbow osteoarthritis received three intravenous doses of allogeneic canine mesenchymal stem cells via an open-label clinical trial. Primary outcome measures collected over a 6-month study period included objective gait analysis, accelerometry, owner questionnaires and joint fluid analysis. Results No acute adverse events were observed following repeated intravenous treatment with allogeneic mesenchymal stem cells. A significant improvement in mean client-specific outcome measure (CSOM) activity score and CSOM behaviour score was observed when pre-treatment values were compared with post-treatment values (day >28). In contrast, mean peak vertical force significantly decreased from baseline to post-treatment (>day 28). Weekly activity counts did not show a significant difference between baseline to post-treatment time points. Synovial fluid biomarkers did not change during treatment, and labelled mesenchymal stem cells were rarely detected in synovial fluid samples collected after mesenchymal stem cell administration. Clinical Significance For dogs with naturally occurring elbow osteoarthritis, intravenous administration of mesenchymal stem cells was clinically well tolerated. While some subjective outcome measures showed significant improvements, objective outcome measures did not confirm similar changes. Further research is needed before intravenous mesenchymal stem cells can be recommended as a treatment for elbow osteoarthritis in dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study

Olsen

Johnson

Webb

et al. 2019

Vet Comp Orthop Traumatol

View full text Add to dashboard Cite

show abstract

“…In smaller dog breeds, the most common cardiac disease is the degenerative valvular disease, which is often complicated by ventricular dilation and dysfunction (233). Petchdee and Sompeewong investigated the effect of IV administration of puppy deciduous teeth derived stem cells on the degenerative valvular disease (234). Their results showed an improvement in the left ventricular ejection fraction, but this was a small study, and more studies will be needed to establish any potential positive effects.…”

Section: Cardiac Diseasesmentioning

confidence: 99%

Stem Cells in Veterinary Medicine—Current State and Treatment Options

et al. 2020

View full text Add to dashboard Cite

Regenerative medicine is a branch of medicine that develops methods to grow, repair, or replace damaged or diseased cells, organs or tissues. It has gained significant momentum in recent years. Stem cells are undifferentiated cells with the capability to self-renew and differentiate into tissue cells with specialized functions. Stem cell therapies are therefore used to overcome the body's inability to regenerate damaged tissues and metabolic processes after acute or chronic insult. The concept of stem cell therapy was first introduced in 1991 by Caplan, who proposed that massive differentiation of cells into the desired tissue could be achieved by isolation, cultivation, and expansion of stem cells in in vitro conditions. Among different stem cell types, mesenchymal stem cells (MSC) currently seem to be the most suitable for therapeutic purposes, based on their simple isolation and culturing techniques, and lack of ethical issues regarding their usage. Because of their remarkable immunomodulatory abilities, MSCs are increasingly gaining recognition in veterinary medicine. Developments are primarily driven by the limitations of current treatment options for various medical problems in different animal species. MSCs represent a possible therapeutic option for many animal diseases, such as orthopedic, orodental and digestive tract diseases, liver, renal, cardiac, respiratory, neuromuscular, dermal, olfactory, and reproductive system diseases. Although we are progressively gaining an understanding of MSC behavior and their mechanisms of action, some of the issues considering their use for therapy are yet to be resolved. The aim of this review is first to summarize the current knowledge and stress out major issues in stem cell based therapies in veterinary medicine and, secondly, to present results of clinical usage of stem cells in veterinary patients.

show abstract

“…Furthermore, the use of allogeneic MSC has shown to be effective and safe in canine diseases [26]. In addition, adult MSCs exhibit attractive immunomodulatory properties in degenerative diseases in animals [27]. This is the case of ASCs, a type of MSC, which in addition to the cellular and molecular traits of BM-MSC, exhibits robust immunosuppressive activity, mediated by induction of the production of Tregs [28] and the selective release of several types of growth factors [29][30][31][32][33].…”

Section: Introductionmentioning

confidence: 99%

Multidose intramuscular allogeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study

Enciso

Amiel-Pérez

Pando³

et al. 2019

Vet World

View full text Add to dashboard Cite

Aim:The aim of this pilot study was to evaluate the therapeutic and safety performance of an intramuscular treatment protocol of multidose of allogeneic adipose stem cells (ASCs) isolated, characterized, and expanded ex vivo from a healthy canine donor. Materials and Methods:Twelve dogs diagnosed with canine atopic dermatitis (CAD) were intramuscularly treated with 0.5×10 6 of cryopreserved ASCs from a healthy immunized young canine Ehrlichia canis free donor weekly for 6 weeks. Treatment efficacy was evaluated by the pruritus index and the CAD Lesion Index (CADLI) test. Safety and adverse effects were determined by injection site reaction, weight, blood chemistry, liver function, and whole blood count.Results: Canine ASCs obtained from a donor met the minimum qualities required for this type of cells and showed viability of 90% after thawing. The efficacy of the CADLI score and the pruritus index in 12 dogs with atopic dermatitis was statistically significant efficacy. No adverse reactions were observed at the intramuscular application site, or in relation to animal weight, blood cell populations, or liver and renal function. Conclusion:These results suggest that intramuscular administration of cryopreserved ASCs to dogs with atopic dermatitis is a promising cellular therapeutic product for the relief of the symptoms of this disease; however, the duration of the effects obtained with this dose and with other doses should be evaluated, as well as possible immune reactions. As far as we know, this is the first report of the use of multiple intramuscular doses cryopreserved ASCs to treat atopic dermatitis.

show abstract

Intravenous administration of puppy deciduous teeth stem cells in degenerative valve disease

Cited by 11 publications

References 29 publications

Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study

Evaluation of Intravenously Delivered Allogeneic Mesenchymal Stem Cells for Treatment of Elbow Osteoarthritis in Dogs: A Pilot Study

Stem Cells in Veterinary Medicine—Current State and Treatment Options

Multidose intramuscular allogeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study

Contact Info

Product

Resources

About